Cas:1078129-57-3 8-fluoro-4-(3-methoxypropoxy)-6-methyl-N-[(3R)-piperidin-3-yl]-N-propan-2-ylquinoline-2-carboxamide manufacturer & supplier

Chemical Name:8-fluoro-4-(3-methoxypropoxy)-6-methyl-N-[(3R)-piperidin-3-yl]-N-propan-2-ylquinoline-2-carboxamide

CAS.NO:1078129-57-3

Synonyms:(R)-8-Fluoro-N-isopropyl-4-(3-methoxypropoxy)-6-methyl-N-(piperidin-3-yl)quinoline-2-carboxamide

Molecular Formula:C₂₃H₃₂FN₃O₃

Molecular Weight:417.51700

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:63.69000

Exact Mass:417.24300

LogP:4.02900

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (R)-8-Fluoro-N-isopropyl-4-(3-methoxypropoxy)-6-methyl-N-(piperidin-3-yl)quinoline-2-carboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(R)-8-Fluoro-N-isopropyl-4-(3-methoxypropoxy)-6-methyl-N-(piperidin-3-yl)quinoline-2-carboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(R)-8-Fluoro-N-isopropyl-4-(3-methoxypropoxy)-6-methyl-N-(piperidin-3-yl)quinoline-2-carboxamide Use and application,(R)-8-Fluoro-N-isopropyl-4-(3-methoxypropoxy)-6-methyl-N-(piperidin-3-yl)quinoline-2-carboxamide technical grade,usp/ep/jp grade.

Related News: Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. 8-fluoro-4-(3-methoxypropoxy)-6-methyl-N-[(3R)-piperidin-3-yl]-N-propan-2-ylquinoline-2-carboxamide manufacturer Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms. 8-fluoro-4-(3-methoxypropoxy)-6-methyl-N-[(3R)-piperidin-3-yl]-N-propan-2-ylquinoline-2-carboxamide supplier Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms. 8-fluoro-4-(3-methoxypropoxy)-6-methyl-N-[(3R)-piperidin-3-yl]-N-propan-2-ylquinoline-2-carboxamide vendor Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. 8-fluoro-4-(3-methoxypropoxy)-6-methyl-N-[(3R)-piperidin-3-yl]-N-propan-2-ylquinoline-2-carboxamide factory Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.